Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus in KRAS-mutant NSCLC
NCT00818675Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2009
- Primary completion
- Aug 2012
- Modality
- Classical Binding Small Molecules
01
Overview
A Phase 2 trial of ridaforolimus in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Mar 2009; status: terminated.
02
Drugs
ridaforolimus
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00818675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00818675.